Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2021 Jan 29;110(3):792–803. doi: 10.1016/j.ijrobp.2021.01.033

Figure 1.

Figure 1.

Kaplan-Meier survival curves for A. Overall survival (OS) among patients undergoing dose-intensified targeting of the combined hypercellular (TVHCV) and hyperperfused (TVCBV) tumor (n=13) B. Progression-free survival (PFS) among patients undergoing dose-intensified targeting of the combined hypercellular and hyperperfused tumor (n=13) C. Overall survival among all patients (n=23)